Transenterix Inc (NYSEMKT:TRXC) Stock Price While Sentiment Increases to 2.15

TransEnterix, Inc. (NYSEAMERICAN:TRXC) Corporate Logo

“Big money” Positions

“Big money sentiment for Transenterix Inc (NYSEMKT:TRXC) in Q2 2018 increased to 2.15, filings reveal. That’s up 0.51, from 2018Q1’s 1.64. 71 institutional investors started new and increased holdings, while 33 decreased and sold stock positions in Transenterix Inc so the sentiment increased. Funds own 59.38 million shares, up from 50.28 million shares in 2018Q1. Funds holding Transenterix Inc in top 10 decreased from 3 to 2 for a decrease of 1. 15 Investors Sold All; 18 Reduced Holdings; 24 increased stakes while 47 institutional investors bought stakes.

Significant Transenterix Inc Shareholders

Sv Health Investors Llc owns 7.55 million shares in Transenterix Inc as of Q2 2018. Transenterix Inc’s shareholder Aisling Capital Llc owns 6.39 million shares as of Q2 2018. Hamilton Lane Advisors Llc reported 115,000 shares. The New York-based fund Global X Management Co Llc have invested about 0.2% of the investment manager’s stock portfolio in Transenterix Inc. The California-based fund Eam Investors Llc holds 245,801 shares or 0.17% of their long stock exposure.

TransEnterix, Inc., a medical device company, focuses on the development and commercialization of surgical robotic systems.The firm is valued at $652.68 million. The firm offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe.Last it reported negative earnings. It also develops SurgiBot System, a single-port, robotically enhanced laparoscopic surgical platform.

TRXC is hitting $3.02 during the last trading session, after decreased 5.03%.TransEnterix, Inc. has volume of 2.48M shares. Since December 8, 2017 TRXC has risen 330.95% and is uptrending. TRXC outperformed by 315.33% the S&P 500.

On March, 5. Investors wait TransEnterix, Inc. (NYSEAMERICAN:TRXC) to publish its quarterly earnings, Zacks reports. This year’s EPS analyst estimate is anticipated to be $-0.06. That is 85.00 % up compareed to $-0.4 EPS for last year. Wall Street forecasts 0.00 % EPS growth as of March, 5.

10,000 were reported by Zacks Management. Raymond James Assocs owns 73,466 shs for 0% of their capital. Lifeplan Gp invested in 0% or 1,000 shs. Moreover, Amalgamated Bank has 0% invested in TransEnterix, Inc. (NYSEAMERICAN:TRXC). Gotham Asset Mngmt Ltd Llc invested 0% in TransEnterix, Inc. (NYSEAMERICAN:TRXC). Sg Americas invested in 0.01% or 136,005 shs. 7.45 million are owned by Vanguard Gru Inc. Fifth Third State Bank owns 6,450 shs for 0% of their capital. California State Teachers Retirement System has 0% invested in TransEnterix, Inc. (NYSEAMERICAN:TRXC). State Street, a Massachusetts-based fund reported 3.29M shs. Jpmorgan Chase & Com has invested 0.01% in TransEnterix, Inc. (NYSEAMERICAN:TRXC). Gru owns 101,608 shs for 0% of their capital. Essex Ltd owns 13,166 shs. Stifel Financial has 73,728 shs for 0% of their capital. Moreover, Fincl Architects has 0.01% invested in TransEnterix, Inc. (NYSEAMERICAN:TRXC).

TransEnterix, Inc. registered $30.67 million net activity with 0 insider buys and 8 insider sales since June 18, 2018. $1.78 million worth of TransEnterix, Inc. (NYSEAMERICAN:TRXC) shs were sold by Pope Todd. Starling William N JR sold $22.72 million worth of stock or 3.61 million shs.

For more TransEnterix, Inc. (NYSEAMERICAN:TRXC) news announced recently go to:,,, or The titles are as follows: “TransEnterix to Showcase First Digital Laparoscopic Surgical Platform, the Senhance Surgical System, at American College of Surgeons Clinical Congress 2018 – Business Wire” announced on October 16, 2018, “TransEnterix (TRXC) Q2 Revenue Expected to be $6-$6.3 Million –” on July 02, 2018, “Daily Biotech Pulse: Nantkwest Reports Positive Cancer Vaccine Trial Results, Sarepta Offering – Benzinga” with a publish date: November 08, 2018, “TransEnterix Schedules Third Quarter 2018 Financial and Operating Results Conference Call for November 8, 2018 – Business Wire” and the last “TransEnterix Provides 2017 Year End Corporate Update – Business Wire” with publication date: January 08, 2018.

TransEnterix, Inc. (NYSEAMERICAN:TRXC) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.